Cargando…
India Declines Patent Extension Application of Bedaquiline: A Remarkable Step Towards Tuberculosis Elimination
In a pivotal decision, an application to extend the patent on bedaquiline submitted by the pharmaceutical company Johnson & Johnson was denied by the Indian Patent Office, an essential drug for the treatment of tuberculosis. This development marks the conclusion of eight years of drug exclusivit...
Autor principal: | Yadav, Sankalp |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692960/ https://www.ncbi.nlm.nih.gov/pubmed/38046693 http://dx.doi.org/10.7759/cureus.48146 |
Ejemplares similares
-
Primary Rifampicin Mono-Resistant Extrapulmonary Tuberculosis of the Knee Without Pulmonary Involvement: One of the First Cases of Its Type in an Immunocompetent Male
por: Yadav, Sankalp
Publicado: (2023) -
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021) -
Where India Stands in Malaria Elimination?
por: Dhiman, Sunil, et al.
Publicado: (2014) -
Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017) -
Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis
por: Gaida, Razia, et al.
Publicado: (2020)